Serene W. Chen

Serene W. Chen

Auto-generated profile, based on publicly available information

Serene W. Chen

Department of Chemistry, University of Cambridge , Lensfield Road, Cambridge CB2 1EW, United Kingdom

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2017 in Science
Verified
Journal Article
Open access
PDF file
Giuliana FuscoGiuliana Fusco
Giuliana Fusco
SCSerene W. Chen
Serene W. Chen
PWPhilip T.F. Williamson
Philip T.F. Williamson
RCRoberta Cascella
Roberta Cascella
MPMichele Perni
Michele Perni
ASAlfonso De Simone
Alfonso De Simone
A structural look at α-synuclein oligomers: Fibrillar aggregates of the protein α-synuclein (αS) are the major constituents of Lewy bodies in Parkinson's disease. However, small oligomers that accumulate during the process of fibril formation are thought to cause the neuronal toxicity associated with the onset and progression of Parkinson's disease. Little is known about the detailed structural properties of αS oligomers and the molecular mechanisms that lead to their toxicity. Fusco et al. report the structural characterization of two forms of αS oligomers, which elucidates the fundamental structural elements giving rise to neuronal toxicity. Science , this issue p. 1440

8 April 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SCSerene W. Chen
Serene W. Chen
SDSrdja Drakulic
Srdja Drakulic
EDEmma Deas
Emma Deas
MOMyriam Ouberai
Myriam Ouberai
FAFrancesco Antonio Aprile
Francesco Antonio Aprile
NCNunilo Cremades
Nunilo Cremades
Significance: Certain oligomeric species generated during the self-assembly of specific proteins into ordered fibrillar aggregates are likely to be key players in the initiation and spreading of neurodegenerative diseases. We have purified stable toxic oligomeric species of α-synuclein and defined and minimized their degree of heterogeneity, which has allowed us to identify distinct subgroups of oligomers and determine their structural properties and three-dimensional molecular architectures. All the oligomeric subgroups possess approximately cylindrical architectures with marked similarities to amyloid fibrils, suggesting that these types of oligomers are kinetically trapped during protein self-assembly. The relative stabilities and inherent pathological roles of different amyloid oligomers are likely to result from the multiplicity of pathways of the misfolding process and the remarkably slow rates of structural conversions.

1 March 2016 in Antioxidants & Redox Signaling
Verified
Journal Article
Open access
EDEmma Deas
Emma Deas
NCNunilo Cremades
Nunilo Cremades
PAPlamena R. Angelova
Plamena R. Angelova
MLMarthe H.R. Ludtmann
Marthe H.R. Ludtmann
ZYZhi Yao
Zhi Yao
AAANDREY Abramov
ANDREY Abramov
Aims: Protein aggregation and oxidative stress are both key pathogenic processes in Parkinson's disease, although the mechanism by which misfolded proteins induce oxidative stress and neuronal death remains unknown. In this study, we describe how aggregation of alpha-synuclein (α-S) from its monomeric form to its soluble oligomeric state results in aberrant free radical production and neuronal toxicity. Results: We first demonstrate excessive free radical production in a human induced pluripotent stem-derived α-S triplication model at basal levels and on application of picomolar doses of β-sheet-rich α-S oligomers. We probed the effects of different structural species of α-S in wild-type rat neuronal cultures and show that both oligomeric and fibrillar forms of α-S are capable of generating free radical production, but that only the oligomeric form results in reduction of endogenous glutathione and subsequent neuronal toxicity. We dissected the mechanism of oligomer-induced free radical production and found that it was interestingly independent of several known cellular enzymatic sources. Innovation: The oligomer-induced reactive oxygen species (ROS) production was entirely dependent on the presence of free metal ions as addition of metal chelators was able to block oligomer-induced ROS production and prevent oligomer-induced neuronal death. Conclusion: Our findings further support the causative role of soluble amyloid oligomers in triggering neurodegeneration and shed light into the mechanisms by which these species cause neuronal damage, which, we show here, can be amenable to modulation through the use of metal chelation. Antioxid. Redox Signal . 24, 376–391.

17 January 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MPMichele Perni
Michele Perni
CGCéline Galvagnion
Céline Galvagnion
AMAlexander Maltsev
Alexander Maltsev
GMGeorg Meisl
Georg Meisl
MMMartin B. D. Müller
Martin B. D. Müller
CDChristopher M. Dobson
Christopher M. Dobson
The self-assembly of α-synuclein is closely associated with Parkinson’s disease and related syndromes. We show that squalamine, a natural product with known anticancer and antiviral activity, dramatically affects α-synuclein aggregation in vitro and in vivo. We elucidate the mechanism of action of squalamine by investigating its interaction with lipid vesicles, which are known to stimulate nucleation, and find that this compound displaces α-synuclein from the surfaces of such vesicles, thereby blocking the first steps in its aggregation process. We also show that squalamine almost completely suppresses the toxicity of α-synuclein oligomers in human neuroblastoma cells by inhibiting their interactions with lipid membranes. We further examine the effects of squalamine in a Caenorhabditis elegans strain overexpressing α-synuclein, observing a dramatic reduction of α-synuclein aggregation and an almost complete elimination of muscle paralysis. These findings suggest that squalamine could be a means of therapeutic intervention in Parkinson’s disease and related conditions. Significance Parkinson’s disease is characterized by the presence in brain tissues of aberrant aggregates primarily formed by the protein α-synuclein. It has been difficult, however, to identify compounds capable of preventing the formation of such deposits because of the complexity of the aggregation process of α-synuclein. By exploiting recently developed highly quantitative in vitro assays, we identify a compound, squalamine, that blocks α-synuclein aggregation, and characterize its mode of action. Our results show that squalamine, by competing with α-synuclein for binding lipid membranes, specifically inhibits the initiation of the aggregation process of α-synuclein and abolishes the toxicity of α-synuclein oligomers in neuronal cells and in an animal model of Parkinson’s disease.

1 January 2017
Verified
Book Chapter
Closed access
NCNunilo Cremades
Nunilo Cremades
SCS W Chen
S W Chen
CDC M Dobson
C M Dobson

4 February 2016 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
MHMathew Horrocks
Mathew Horrocks
SLSteven F. Lee
Steven F. Lee
SGSonia Gandhi
Sonia Gandhi
NMNadia K. Magdalinou
Nadia K. Magdalinou
SCSerene W. Chen
Serene W. Chen
DKDavid Klenerman
David Klenerman
The misfolding and aggregation of proteins into amyloid fibrils characterizes many neurodegenerative disorders such as Parkinson’s and Alzheimer’s diseases. We report here a method, termed SAVE (single aggregate visualization by enhancement) imaging, for the ultrasensitive detection of individual amyloid fibrils and oligomers using single-molecule fluorescence microscopy. We demonstrate that this method is able to detect the presence of amyloid aggregates of α-synuclein, tau, and amyloid-β. In addition, we show that aggregates can also be identified in human cerebrospinal fluid (CSF). Significantly, we see a twofold increase in the average aggregate concentration in CSF from Parkinson’s disease patients compared to age-matched controls. Taken together, we conclude that this method provides an opportunity to characterize the structural nature of amyloid aggregates in a key biofluid, and therefore has the potential to study disease progression in both animal models and humans to enhance our understanding of neurodegenerative disorders.